Select Your Region
LACTEL® 50:50 DL-PLGE, IV 0.55-0.75 is a non-GMO pharmaceutical excipient with a polymer composition of 50 mol % D,L-lactide and 50 mol % Glycolide with an ester end group and no added preservatives. It is formulated by Evonik as a white to tan pelletized solid with an inherent viscosity of 0.55─0.75 dL/g in HFIP and a degradation time of 3 months max.
LACTEL® 50:50 DL-PLGE, IV 0.55-0.75 is a 100% bioresorbable PLGA-based copolymer containing a 50:50 mol ratio of D,L-Lactide and Glycolide, providing a uniform degredation rate of 3 months for controlled drug delivery. It is compatible with a range of pharmaceutical substance types, including peptides, proteins, nanoparticles, and microparticles for the formulation of long-acting injectable formulations in veterinary medicine and human generic drug formulations. As a non-solvent purified poly (D,L-lactide-co-glycolide) polymer with an amorphous nature, it exhibits enhanced adaptability and versatility in formulations with superior stability properties. LACTEL® 50:50 DL-PLGE, IV 0.55-0.75 is non-GMO certified and has no added preservatives.
Physical state: Solid
Form: Granules
Color: White to light tan
Inherent viscosity (IV) dL/g: 0.55─0.75 (in HFIP)
Degradation time: <3 months
Crystalline Melt Transition (°C): Amorphous
Glass transition temp (°C): 45─50
Solubility (@ 5% w/w): Dichloromethane, tetrahydrofuran, ethyl acetate, chloroform, hexafluoroisopropanol, acetone
Approx. resorption (months): 1─2
Density (g/mL): 1.34
Tensile Strength (psi): 6000─8000
Elongation (%): 3─10
Modulus (psi): 2─4x10⁵
CAS No. 26780-50-7
Primary Chemistry:
Poly(DL-lactide-co-glycolide)
Human generic drug formulations
Long-acting injectable formulations
Price sensitive applications
veterinary medicine
We’ve detected that you are located in a different region than the region selected on the website. Would you like to change your region?
Current Region: English - United States